December 10, 2024 – Hzymes, a leading domestic company in the industrialization of special enzymes in the biopharmaceutical field, and Dapu Biotech, a leader in microfluidic technology, announced today that they have reached a strategic cooperation. The two parties will integrate their respective advantages in enzyme evolution methods and tools to form a complete solution and actively carry out business synthesis to meet the widespread and urgent market demand for enzyme evolution, promoting innovation and application of enzyme evolution technology.

The two parties will rely on gene synthesis platforms and enzyme modification platforms to jointly launch enzyme evolution-related services, covering molecular enzymes (such as Taq enzyme, reverse transcriptase, T7 transcriptase, etc.) and industrial enzymes (such as oxidases, proteases, amylases, etc.) commonly used in the market. At the same time, it also covers a series of services including mutation library construction, high-throughput screening method construction, library high-throughput screening, and post-screening verification. This will help enterprises to carry out more efficient enzyme evolution work, effectively improving quality and efficiency.

The enzyme modification platform is an innovative enzyme engineering solution that integrates multiple core technologies in the field of enzyme engineering, including fluorescence-activated droplet sorting, microplate screening, partitioned self-replicating technology, and computer-aided rational design. With the synergistic application of these technologies, the platform significantly improves the efficiency and success rate of enzyme modification, meeting a variety of enzyme needs, such as enhancing their activity, stability, and selectivity.

In addition, Hzymes has a GMP-standard large-scale fermentation and purification process platform, as well as a large-scale production factory for enzyme-catalyzed pharmaceutical intermediates, which can provide technical assurance for the large-scale and stable production preparation of evolved enzymes and their catalytic products.


Dr. Guangyu Yang, Chairman and CEO of Hzymes, said:

“ Hzymes has been deeply engaged in the innovation of special enzyme raw materials for many years, accumulating a wealth of valuable experience in enzyme modification and evolution. This strong alliance with Dapu Biotech can provide scientists and researchers in the life sciences field with a complete set of enzyme evolution solutions, equipment, reagents, and technical consulting services. Enzyme modification technology is a foundational technology in the life sciences field. The enzyme modification services jointly launched by Hzymes and Dapu will accelerate the progress of scientific research in the entire life sciences field, especially in the IVD and synthetic biology fields.”

Dr. Xiaonan Xu, Founder of Dapu Biotech, said:

“Dapu Biotech is committed to exploration and innovation in the life sciences field, focusing on building a complete solution provider that integrates instruments, reagents, and microfluidic chips. Our technical capabilities in synthetic biology are continuously improving, and we are actively seeking cooperation opportunities with outstanding enterprises in the industry to jointly promote technological innovation and development. We will integrate the advantages of both parties in enzyme evolution methods and experimental equipment and materials to jointly develop more outstanding products and services. This can not only accelerate the progress of enzyme evolution research, promote innovation and application of related technologies, but also inject new vitality into the basic research and industrial development of synthetic biology, contributing to the progress of global life sciences.”

About Dapu Biotech (DPBIO)

Dapu Biotech was incubated at the Hong Kong University of Science and Technology and was established in 2018. It has now become a leading enterprise in high-throughput droplet microfluidic technology in China. The company has R&D and production centers in Shenzhen and Jiaxing, with a research and development team of nearly a hundred people, focusing on applying droplet microfluidic technology to the field of life health, and is committed to becoming a complete solution provider integrating the research and development and production of microfluidic chips, instruments, and reagents.

The company has commercialized several scientific instruments based on droplet microfluidic technology, including the CytoSpark™ Droplet Microfluidic High-throughput Screening System, OMNIdrop System, Galaxy Single Cell Analysis System, Nebula dPCR System, and Exostar Extracellular Vesicles Analysis System, which can be applied to antibody screening, directed evolution of enzymes, strain screening, small molecule compound screening, cancer research, tumor early screening, virus quantification, and biological product quality inspection. It has served more than 100 well-known top biopharmaceutical, in vitro diagnostic companies, universities, research institutes, and national key laboratories, achieving several firsts in the domestic and international biopharmaceutical field, and has been widely recognized in the industry.

About Hzymes Biotech (Hzymes)

Hzymes Biotechnology Co., Ltd. is a high-tech enterprise specializing in the research and development, production, application, and technical services of core raw materials in biopharmaceuticals and in vitro diagnostics. Since its establishment, the company has always adhered to the core concept of research and development, relying on its independent core technologies, and has technology platforms such as enzyme gene mining and performance characterization, enzyme molecular optimization and modification, enzyme gene high-throughput screening, organic synthesis, synthetic biology, and antigen-antibody research and preparation.

Since its establishment in 2015, the company has accumulated a total investment of nearly 10 billion yuan, with a current valuation of nearly 50 billion yuan. The company has developed marketing and R&D production centers in Shanghai, Wuhan, Yichang, and other places, presenting a situation where multiple technology platforms and product fields are advancing in parallel, becoming a leading enterprise in the upstream raw material industry of biopharmaceuticals and in vitro diagnostics.